ClinicalTrials.gg
CompletedNCT02544750Updated Jul 14, 2022Results posted

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

A Phase 3 interventional study of GWP42003-P in Tuberous Sclerosis Complex and Seizures, sponsored by Jazz Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 1 Year to 65 Years. Per ClinicalTrials.gov, last updated 2022-07-14.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
199
Allocation
Not applicable
Ages
1 Year to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies in Tuberous Sclerosis with a site in United States — 8 open to participants now, 15 under way, 1 of them phase 3. Tuberous Sclerosis · United States.

Enrollment
4th of 47
199 · median 52
Started
2016
with 4 others
Phase 3
10 of 63
none open now
Registered
30th of 63
by date
Lead sponsor
5 of 63
Jazz Pharmaceuticals

Among the 63 studies in Tuberous Sclerosis with a site in United States, this one is the 4th largest by enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2016, is one of 10 in phase 3, and was the 30th registered.

Tuberous Sclerosis

115 studies on the registry are indexed under Tuberous Sclerosis; 27 are open to participants now.

Browse Tuberous Sclerosis studies →

Open to participants now

8 of the 63 studies in Tuberous Sclerosis with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Tuberous Sclerosis studies recruiting now, 10 (48%) set no upper age limit and 8 (38%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 1 Year to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Tuberous Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The open-label extension phase only will be described in this record. All participants will receive the same dose of GWP42003-P. However, investigators may subsequently decrease or increase the participant's dose until the optimal dose is found.

03

Conditions studied

  • Tuberous Sclerosis Complex
  • Seizures
04

Who can participate

Ages eligible
1 Year to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Completion of the GWEP1521 Blinded Phase
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
199 participants (actual)

Study arms

  • Experimental
    GWP42003-P

    100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening). Participants will be dosed up to a maximum of 50 mg/kg/day. Dose may be lower if Investigator judges benefit and/or tolerability issues.

    Drug: GWP42003-P

Interventions

  • Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

    Also known as: Cannabidiol, CBD

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE)

    An adverse event (AE) was defined as any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings), or diagnosis or worsening of a pre-existing condition, which occurred following screening and at any point up to the post-treatment safety follow-up visit, which may or may not be related to the IMP. An AE that started, or worsened in severity or seriousness, following the first dose of IMP was considered a TEAE. A serious AE was defined as any AE that results in any of the following outcomes: death, life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or cancer, any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above, or an event that changes the risk/benefit ratio of the study.

    Time frame: OLE Day 1 up to 4 years

  2. Number of Participants With Any TEAE, by Severity

    An adverse event (AE) was defined as any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings), or diagnosis or worsening of a pre-existing condition, which occurred following screening and at any point up to the post-treatment safety follow-up visit, which may or may not be related to the IMP. An AE that started, or worsened in severity or seriousness, following the first dose of IMP was considered a TEAE. Grade 1 (Mild) is defined as asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 (Moderate) is defined as minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental activities of daily living (ADL). Grade 3 (Severe) is defined as medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL.

    Time frame: OLE Day 1 up to 4 years

Secondary outcomes

  1. Percent Change From Baseline in the Number of TSC-associated Seizures During the OLE Treatment Period

    TSC-associated seizures include: focal motor seizures without impairment of consciousness or awareness; focal seizures with impairment of consciousness or awareness; focal seizures evolving to bilateral generalized convulsive seizures and tonic-clonic, tonic, clonic or atonic seizures. A negative percent change from baseline indicates improvement.

    Time frame: OLE Day 1 up to 4 years

  2. Number of Participants Considered Treatment Responders During the OLE Treatment Period

    Treatment responders were defined as those participants with a ≥50% reduction from baseline in TSC-associated seizure frequency, during the treatment period, for participants who had not withdrawn from the trial during the treatment period. TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that were countable. Participants who withdrew from the trial during the treatment period were considered non-responders.

    Time frame: OLE Day 1 up to 4 years

  3. Caregiver Global Impression of Change (CGIC) and Subject Global Impression of Change (SGIC) Score During the OLE Treatment Period

    The CGIC comprised the following question to be rated on a 7-point scale (1, Very Much Improved; 2, Much Improved; 3, Slightly Improved; 4, No Change; 5, Slightly Worse; 6, Much Worse; 7, Very Much Worse): "Since your child started treatment, please assess the status of your child's overall condition (comparing their condition now to their condition before treatment)." The SGIC comprised the following question to be rated on a 7-point scale (1, Very Much Improved; 2, Much Improved; 3, Slightly Improved; 4, No Change; 5, Slightly Worse; 6, Much Worse; 7, Very Much Worse): "Since you started treatment, please assess the status of your overall condition (comparing your condition now to your condition before treatment)." The average CGIC and SGIC scores are being reported, with higher values indicating worse condition.

    Time frame: OLE Day 1 and up to 4 years

  4. Percent Change From Baseline in Total Seizure Frequency During the OLE Treatment Period

    Total seizures included all seizure types, eg. combination of TSC-associated and other seizures. TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that were countable. A negative percent change from baseline indicates improvement in total seizure frequency.

    Time frame: OLE Day 1 up to 4 years

07

Results

Posted Jul 14, 2022

Participant flow

A total of 199 participants with tuberous sclerosis complex (TSC) who met all inclusion criteria and no exclusion criteria and completed the double-blind study GWEP1521 (NCT02544763) were enrolled into this Open-label Extension (OLE) study to receive GWP42003-P.

Participant flow — Overall Study
MilestoneGWP42003-P (Double-blind Phase)Placebo (Double-blind Phase)
Started12475
Completed2212
Not completed10263
Withdrew: Physician decision31
Withdrew: Other reasons6939
Withdrew: Met withdrawal criteria22
Withdrew: Transition to commercial product10
Withdrew: Withdrawal by parent/guardian87
Withdrew: Adverse event810
Withdrew: Withdrawal by subject104
Withdrew: Lost to follow-up10

Outcome measures

PrimaryNumber of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE)

An adverse event (AE) was defined as any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings), or diagnosis or worsening of a pre-existing condition, which occurred following screening and at any point up to the post-treatment safety follow-up visit, which may or may not be related to the IMP. An AE that started, or worsened in severity or seriousness, following the first dose of IMP was considered a TEAE. A serious AE was defined as any AE that results in any of the following outcomes: death, life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or cancer, any other experience that suggests a significant hazard, contraindication, side effect or precaution that may require medical or surgical intervention to prevent one of the outcomes listed above, or an event that changes the risk/benefit ratio of the study.

Time frame:
OLE Day 1 up to 4 years
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE)
ParticipantsGWP42003-P (Double-blind Phase)Placebo (Double-blind Phase)
Any TEAE11775
Any treatment-related TEAE8060
Any TEAE leading to permanent discontinuation of IMP117
Any treatment-related TEAE leading to permanent discontinuation of IMP97
Any serious TEAE3818
Any treatment-related serious TEAE78
Any fatal TEAEs10
PrimaryNumber of Participants With Any TEAE, by Severity

An adverse event (AE) was defined as any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings), or diagnosis or worsening of a pre-existing condition, which occurred following screening and at any point up to the post-treatment safety follow-up visit, which may or may not be related to the IMP. An AE that started, or worsened in severity or seriousness, following the first dose of IMP was considered a TEAE. Grade 1 (Mild) is defined as asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 (Moderate) is defined as minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental activities of daily living (ADL). Grade 3 (Severe) is defined as medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL.

Time frame:
OLE Day 1 up to 4 years
Reported as:
Count of participants · Participants
Number of Participants With Any TEAE, by Severity
ParticipantsGWP42003-P (Double-blind Phase)Placebo (Double-blind Phase)
Mild TEAE3516
Moderate TEAE6348
Severe TEAE1911
SecondaryPercent Change From Baseline in the Number of TSC-associated Seizures During the OLE Treatment Period

TSC-associated seizures include: focal motor seizures without impairment of consciousness or awareness; focal seizures with impairment of consciousness or awareness; focal seizures evolving to bilateral generalized convulsive seizures and tonic-clonic, tonic, clonic or atonic seizures. A negative percent change from baseline indicates improvement.

Time frame:
OLE Day 1 up to 4 years
Reported as:
Median · percent change
Percent Change From Baseline in the Number of TSC-associated Seizures During the OLE Treatment Period
percent changeGWP42003-P (Double-blind Phase)Placebo (Double-blind Phase)
Percent Change From Baseline in the Number of TSC-associated Seizures During the OLE Treatment Period-55.66 (-86.47 to -12.33)-46.76 (-78.17 to -15.69)
SecondaryNumber of Participants Considered Treatment Responders During the OLE Treatment Period

Treatment responders were defined as those participants with a ≥50% reduction from baseline in TSC-associated seizure frequency, during the treatment period, for participants who had not withdrawn from the trial during the treatment period. TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that were countable. Participants who withdrew from the trial during the treatment period were considered non-responders.

Time frame:
OLE Day 1 up to 4 years
Reported as:
Count of participants · Participants
Number of Participants Considered Treatment Responders During the OLE Treatment Period
ParticipantsGWP42003-P (Double-blind Phase)Placebo (Double-blind Phase)
≥ 50% reduction: Yes7036
≥ 50% reduction: No5439
SecondaryCaregiver Global Impression of Change (CGIC) and Subject Global Impression of Change (SGIC) Score During the OLE Treatment Period

The CGIC comprised the following question to be rated on a 7-point scale (1, Very Much Improved; 2, Much Improved; 3, Slightly Improved; 4, No Change; 5, Slightly Worse; 6, Much Worse; 7, Very Much Worse): "Since your child started treatment, please assess the status of your child's overall condition (comparing their condition now to their condition before treatment)." The SGIC comprised the following question to be rated on a 7-point scale (1, Very Much Improved; 2, Much Improved; 3, Slightly Improved; 4, No Change; 5, Slightly Worse; 6, Much Worse; 7, Very Much Worse): "Since you started treatment, please assess the status of your overall condition (comparing your condition now to your condition before treatment)." The average CGIC and SGIC scores are being reported, with higher values indicating worse condition.

Time frame:
OLE Day 1 and up to 4 years
Reported as:
Mean · score on a scale
Caregiver Global Impression of Change (CGIC) and Subject Global Impression of Change (SGIC) Score During the OLE Treatment Period
score on a scaleGWP42003-P (Double-blind Phase)Placebo (Double-blind Phase)
Caregiver3.2 ± 1.583.4 ± 1.12
Subjects4.0 ± 0.02.7 ± 1.53
Combined Caregiver and Subjects3.2 ± 1.563.3 ± 1.16
SecondaryPercent Change From Baseline in Total Seizure Frequency During the OLE Treatment Period

Total seizures included all seizure types, eg. combination of TSC-associated and other seizures. TSC-associated seizures included: focal motor seizures without impairment of consciousness or awareness (Type 1 focal motor); focal seizures with impairment of consciousness or awareness (Type 2 focal); focal seizures evolving to bilateral generalized convulsive seizures (Type 3 focal); and tonic-clonic, tonic, clonic, or atonic seizures that were countable. A negative percent change from baseline indicates improvement in total seizure frequency.

Time frame:
OLE Day 1 up to 4 years
Reported as:
Median · percent change
Percent Change From Baseline in Total Seizure Frequency During the OLE Treatment Period
percent changeGWP42003-P (Double-blind Phase)Placebo (Double-blind Phase)
Percent Change From Baseline in Total Seizure Frequency During the OLE Treatment Period-55.18 (-84.21 to -11.95)-46.76 (-76.22 to -19.77)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were collected from OLE Day 1 up to 4 years.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Double-blind Phase)1/124 (0.8%)38/124 (30.6%)117/124 (94.4%)
GWP42003-P (Double-blind Phase)0/75 (0%)18/75 (24%)75/75 (100%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventPlacebo (Double-blind Phase)GWP42003-P (Double-blind Phase)
SeizureNervous system disorders12/1244/75
Status epilepticusNervous system disorders9/1241/75
InfluenzaInfections and infestations5/1240/75
PneumoniaInfections and infestations4/1241/75
DehydrationMetabolism and nutrition disorders4/1242/75
Transaminases increasedInvestigations0/1242/75
Adenovirus infectionInfections and infestations2/1240/75
Mental status changesPsychiatric disorders2/1240/75
NeutropeniaBlood and lymphatic system disorders0/1241/75
ThrombocytopeniaBlood and lymphatic system disorders0/1241/75
Most frequent other events
Showing 10 of 71
Most frequent other events
EventPlacebo (Double-blind Phase)GWP42003-P (Double-blind Phase)
DiarrhoeaGastrointestinal disorders50/12443/75
SeizureNervous system disorders40/12419/75
Decreased appetiteMetabolism and nutrition disorders23/12424/75
SomnolenceNervous system disorders15/12424/75
PyrexiaGeneral disorders33/12415/75
VomitingGastrointestinal disorders27/12413/75
NasopharyngitisInfections and infestations19/12416/75
Upper respiratory tract infectionInfections and infestations22/12410/75
CoughRespiratory, thoracic and mediastinal disorders13/12413/75
FatigueGeneral disorders7/12410/75

Baseline characteristics

Age, Continuous
Age, Continuous(years)GWP42003-P (Double-blind Phase)Placebo (Double-blind Phase)Total
Mean12.69 ± 9.6413.92 ± 10.6313.15 ± 10.02
Sex: Female, Male
Sex: Female, Male(Participants)GWP42003-P (Double-blind Phase)Placebo (Double-blind Phase)Total
Female513081
Male7345118
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GWP42003-P (Double-blind Phase)Placebo (Double-blind Phase)Total
White/Caucasian11166177
Black/African American404
American Indian/Alaska Native101
Asian134
Other7613
Baseline Tuberous Sclerosis Complex (TSC)-Associated Seizures
Baseline Tuberous Sclerosis Complex (TSC)-Associated Seizures(Seizures)GWP42003-P (Double-blind Phase)Placebo (Double-blind Phase)Total
Median58.08 (7.7 to 432.0)55.10 (8.0 to 558.0)56.90 (7.7 to 558.0)
Baseline Total Seizures
Baseline Total Seizures(Seizures)GWP42003-P (Double-blind Phase)Placebo (Double-blind Phase)Total
Median59.95 (7.7 to 595.0)56.97 (8.0 to 1660.1)58.90 (7.7 to 1660.1)
08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Publications

  • Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA, O'Callaghan FJ, Wong M, Sahebkar F, Checketts D, Knappertz V; GWPCARE6 Study Group. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol. 2021 Mar 1;78(3):285-292. doi: 10.1001/jamaneurol.2020.4607. PubMed 33346789 ↗
  • Thiele EA, Bebin EM, Filloux F, Kwan P, Loftus R, Sahebkar F, Sparagana S, Wheless J. Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial. Epilepsia. 2022 Feb;63(2):426-439. doi: 10.1111/epi.17150. Epub 2021 Dec 27. PubMed 34957550 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Jun 2021, 57 months.

Results were first posted in Jul 2022, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2015
First posted
Sep 9, 2015
StartActual
Aug 31, 2016
Primary completionActual
Jun 11, 2021
CompletionActual
Jun 11, 2021
Results first posted
Jul 14, 2022
Last update
Jul 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02544750
Responsible party
Sponsor
First posted
Sep 9, 2015
Start date
Aug 31, 2016
Primary completion
Jun 11, 2021
Completion
Jun 11, 2021
Results posted
Jul 14, 2022
Last update
Jul 14, 2022

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion